The IDM - a cross-faculty, multidisciplinary postgraduate health research institute
Based on the UCT Faculty of Health Sciences campus in a 7,100 sqm state-of-the-art facility, we operate in the fields of infectious diseases and molecular medicine.
Clinical research relevant to the needs of Africa's people
The IDM influences health policy and practice by translating our scientific discoveries and applying them in various communities; community relationships and trust are critical.
Capacity building in the IDM
The largest research entity at UCT, the IDM is a national leader in research and health sciences human capital development.
IDM driving world class research
We conduct research at the laboratory-clinic-community interface by engaging a wide range of scientific and clinical disciplines; with 62 consortia linking us with 183 institutions in 22 African countries and 24 countries beyond.
University accredited research institute - Tackling diseases of importance in Africa - Developing people - Impacting health policy and practice
On the anniversary of his birthday, UCT colleagues, family and friends honoured the late Professor Bongani Mayosi with a bibliography, an inaugural lecture and the renaming (and future renovations) of the University of Cape Town’s (UCT) Health Sciences Library, which will now be known as the Bongani Mayosi Health Sciences Library.
The African genome is the oldest, and as such, the most diverse in the world. But Africans have largely been under-represented in neurogenetic studies. The University of Cape Town (UCT) Neuroscience Institute is helping to change that through a range of forward-looking, international, collaborative projects on genetics and the nervous system.
In a move set to revolutionise tuberculosis (TB) diagnosis and treatment by enabling early detection of infectious cases, molecular diagnostics – the technique used to diagnose and monitor a disease – will be taken out of the laboratory and into the community.
The search for better cancer treatments continues, as current options often cause severe side effects. Less than 5% of experimental anticancer drugs are approved for use in humans, but scientists are bringing new technologies to the quest.